Background. During the 2009 pandemic of influenza A virus subtype H1N1 (A[H1N1]pdm09) infection, older individuals were partially protected from severe disease. It is not known whether preexisting antibodies with effector functions such as antibody-dependent cellular cytotoxicity (ADCC) contributed to the immunity observed.
The pandemic emergence of a swine-origin influenza A virus subtype H1N1 during 2009 (A[H1N1]pdm09) resulted in significant human morbidity worldwide [1] [2] [3] [4] [5] . Interestingly, individuals born before 1957 had lower rates of infection and less severe disease than individuals born after this time [2, [6] [7] [8] [9] [10] , presumably from prior exposure to seasonal influenza A virus subtype H1N1 (sH1N1) [11] [12] [13] [14] [15] . The mechanism of natural protection against A(H1N1)pdm09 infection has been largely attributed to cross-neutralizing antibodies and/or T-cell responses induced following prior exposure to sH1N1 strains [11, 12, [16] [17] [18] [19] [20] [21] [22] , but other antibody effector mechanisms may be involved and are unexplored.
Influenza virus hemagglutinin (HA)-specific antibodies have been mainly characterized for their neutralizing capacity. However, these antibodies have other functions, including complement fixation [23, 24] , phagocytosis [25] , and antibody-dependent cellular cytotoxicity (ADCC) [26] [27] [28] [29] [30] . While neutralizing antibodies may target more variable regions found on the globular head of the viral HA, ADCC antibodies may target more conserved regions of the influenza virus HA and other surface proteins [31, 32] . Recently, we developed new assays to measure ADCC antibodies against multiple influenza virus strains [30] . We previously intensively studied ADCC responses in 10 healthy adults to a broad range of influenza virus strains and detected ADCC antibodies to various influenza virus strains in the absence of detectable neutralizing antibodies. However, our previous small human cohort study was limited by unclear exposure to specific influenza viruses. The emergence and rapid spread of A(H1N1)pdm09 provided an opportunity to study the cross-reactivity of ADCC antibodies against influenza virus that were present before the pandemic. We hypothesized that ADCC antibodies to A(H1N1)pdm09 were present in older individuals and may have potentially played a role in reducing the severity of disease due to A(H1N1)pdm09. We studied serum specimens obtained from 93 subjects before the 2009 H1N1 pandemic and from 89 separate unpaired subjects after the 2009 H1N1 pandemic for ADCC to A(H1N1)pdm09. 
METHODS

Serum Samples and Donors
Influenza Virus Antigens and Hemagglutination Inhibition (HI) Assay
Mammalian-cell-expressed recombinant HA proteins were purchased from Sinobiologicals (Shanghai, China). The influenza virus used was a reassortant virus propagated in embryonated hen's eggs expressing the HA and neuraminidase (NA) from A/Auckland/01/2009 (A/California/07/2009-like 2009 pandemic H1N1) with the internal genes from A/Puerto Rico/8/1934 (H1N1). HI assays were performed as previously described [9] .
Plate-Bound ADCC Natural Killer (NK) Cell Activation Assay
We recently described novel ADCC assays that measure antibodymediated NK cell activation [30] , developed as modifications of human immunodeficiency virus-specific ADCC assays [33, 34] . Briefly, 96-well ELISA plate (Nunc, Rochester, NY) were coated overnight at 4°C with purified influenza protein (400 ng/well) in phosphate-buffered saline (PBS). Wells were washed with PBS and incubated with heat-inactivated plasma/sera for 2 hours at 37°C
. Plates were washed with PBS, and 10 6 freshly isolated human healthy donor peripheral blood mononuclear cells (PBMCs) were added to each well. Brefeldin A (5 μg/mL, Sigma, St. Louis, MO), monensin (5 μg/mL, BD Bioscience, San Jose, CA), and CD107a-APC-H7 (H4A3 clone, BD Bioscience, San Jose, CA) were added, and plates were incubated for 5 hours at 37°C with 5% CO 2 . Cells were then incubated with surface antibodies CD3-PerCP (clone SP34-2), CD14-PE-Cy7 (clone M5E2), and CD56-APC (clone B159, all from BD Bioscience) for 30 minutes at room temperature in the dark. Cells were fixed with 1% formaldehyde (Sigma, St. Louis, MO) for 10 minutes and permeabilized using Permeabilizing Solution 2 for 10 minutes (BD Bioscience). Finally, cells were incubated at room temperature for 1 hour with interferon γ (IFN-γ)-AlexaFluor700 (clone B27, BD Bioscience).
Antibody-Dependent Cellular Viral Elimination Assay, Using a Human Respiratory Epithelial Cell Line
As previously described [30] 
Statistical Analyses
Statistical analyses used SPSS, version 18, software (IBM, Armonk, NY) and Prism GraphPad, version 6 (GraphPad Software, San Diego, CA). Data were analyzed by the t test ( Figure 1B and 1C, Figure 2A , and Figure 3 ), 1-way analysis of variance (ANOVA) together with Tukey post hoc tests ( Figure 1D and 1E), 2-way ANOVA together with Bonferroni comparisons ( Figure 5A ), and Pearson product-moment correlation coefficient ( Figure 4 and Figure 5B and 5C). Statistically significant outliers were determined by GraphPad Outlier calculator (α = 0.05). Before 1-way or 2-way ANOVA, data were log 10 -transformed to equalize variances, according to the Levene test. Because previous studies indicated that individuals <45 years of age showed a higher incidence of A(H1N1)pdm09 infection and a greater frequency of hospitalization with severe influenza [2, 6, 7] , we prospectively divided the samples into groups on the basis of age (ie, 1-14, 15-45, and >45 years; Table 1 ).
A(H1N1)pdm09-Specific ADCC Antibodies in Serum Obtained From Individuals Before and After the 2009 A(H1N1) Pandemic
We first assessed ADCC by using a plate-bound NK cell activation assay [30] Figure 1B ). These data confirm that A(H1N1)pdm09 infection results in enhanced A(H1N1)pdm09-specific ADCC antibodies.
During the 2009 A(H1N1) pandemic, older individuals had a reduced incidence of infection with A(H1N1)pdm09, suggestive of a degree of protection against A(H1N1)pdm09 infection [2, [6] [7] [8] [9] [10] . To determine whether older subjects had higher levels of ADCC antibodies before the 2009 A(H1N1) pandemic, we prospectively sorted our data into 3 distinct age groups (1-14, 15-45, and >45 years). For each age group, ADCC responses to sH1N1 (A/Brisbane/59/07) HA protein were similar in samples taken before and after the 2009 A(H1N1) pandemic ( Figure 1F ). In contrast, ADCC-mediated NK cell activation against A (H1N1)pdm09 HA protein was significantly increased for individuals aged 1-14 years (P < .001) and those aged 15- The percentage of NK cells expressing IFN-γ at a single serum dilution is an effective means of comparing ADCC activity between different serum samples but may not accurately quantify the level of ADCC antibodies. Therefore, serial dilutions of each sample were performed, and we determined the dilution at which NK cell activation falls below a threshold of 3 times the background level of activation. We used a randomly selected subset of 30 Previous influenza virus ADCC studies assumed that the proportion of NK cells activated by ADCC antibodies corresponds with the end point titer of ADCC antibodies measured in this assay, but direct evidence is lacking [30] . To determine whether the level of NK cell activation correlates with the ADCC end point titer, we compared the percentage of ADCCactivated NK cells at a 1:10 dilution to the ADCC end point titer for a number of different serum samples. A clear positive association was observed between NK cell activation at a 1:10 dilution and the end point ADCC titer ( Figure 2B ).
In vaccination and infection studies, a HI antibody titer of >40 is generally regarded as protective [35] . Recently, we demonstrated that the presence of cross-reactive ADCC antibodies to influenza virus can be present in the absence of neutralizing antibodies [30] . Interestingly, across this cohort there was no relationship between the ADCC titer to A(H1N1)pdm09 HA and the HI titer against A(H1N1)pdm09 ( Figure 2C ). Eleven of 24 individuals recorded a HI titer of 40 but an ADCC titer of ≥160. Thus, the HI titer does not reflect the level of HA-specific ADCC antibodies, highlighting a potential limitation of solely using HI titer to identify predictive correlates of protection. It is also notable that HI titers to the sH1N1 A/Brisbane/59/07 were higher in the samples obtained before the 2009 pandemic, but ADCC levels to A/Brisbane/59/07 were similar before and after the 2009 pandemic ( Figure 1B) , further emphasizing the poor correlation between HI titers and ADCC antibodies. 
Cross-reactive ADCC Toward 1918-Like Influenza Viruses
We further hypothesized that infection with A(H1N1)pdm09 might also increase the immunity to related H1N1 influenza viruses by inducing cross-reactive ADCC antibodies in older subjects. We compared antibody-mediated NK cell activation against HA proteins from both the 1918 H1N1 HA protein and the 1934 H1N1 strain (A/Puerto Rico/8/1934) HA protein, using a subset of 9 sera taken from individuals aged 15 
DISCUSSION
Novel pandemic influenza viruses emerge regularly, leading to widespread mortality and morbidity. The recent 2009 A (H1N1) pandemic affected individuals <40 years of age more severely than older individuals [2, [6] [7] [8] [9] [10] . This suggests that there is some level of cross-protection against A(H1N1)pdm09 in older individuals that is not found in younger individuals. Although studies have shown that neutralizing antibodies and T-cell responses are critical in cross-protection [12, 13, 17, 21, 36] , here we show that other antibody effector mechanisms, such as ADCC, may play an important role. Sera from individuals >45 years of age commonly contained preexisting ADCC antibodies to A(H1N1)pdm09. These ADCC antibodies not only activated NK cells but also eliminated A(H1N1)pdm09-infected respiratory cells. Indeed, levels of A(H1N1)pdm09-specific ADCC antibodies were significantly increased following the 2009 A(H1N1) pandemic. The ability of ADCC antibodies to protect against novel influenza viruses is an important area for future research. Recent animal model studies found that seasonal influenza virus infection provides some protection from challenge with A (H1N1)pdm09 and that nonneutralizing antibodies may be involved [11, 17, [37] [38] [39] . A higher titer of A(H1N1)pdm09-specific binding antibodies is induced by infection with sH1N1 that circulated before 1950 [11] . sH1N1 infection induced partial protection against subsequent challenge with A(H1N1)pdm09 among macaques in the absence of detectable HI antibodies [17] . Although T-cell immunity likely plays a role in the protection observed, subsequent analysis of serum samples from that macaque study by our group found that ADCC antibodies induced by the initial sH1N1 infection were cross-reactive with A (H1N1)pdm09 (unpublished data). We found that ADCC responses to 2 distinct sH1N1 viruses correlated with A(H1N1) pdm09-specific ADCC in older individuals. This suggests that prior exposure to seasonal influenza virus infections in older individuals induces cross-reactive A(H1N1)pdm09-specific ADCC. Future studies in animal models can now focus on passive transfer of monoclonal nonneutralizing antibodies that mediate ADCC, to define a role for ADCC in protective immunity.
HA-specific neutralizing antibodies generally recognize highly variable antigenic regions on the globular head of HA and tend to be highly specific for a particular strain of influenza virus. We speculate that ADCC antibodies against conserved regions of influenza virus HA may provide partial crossprotection from a range of influenza virus strains. We found no correlation between HI titers and HA-specific ADCC antibodies; this was expected since HI assays assess the binding of the antibody Fab region to bind antigen, whereas the NK cell assay measures binding of the antibody Fc region to CD16 on NK cells. Antibodies frequently target regions outside the receptorbinding domain of HA, and elderly individuals have a greater antibody diversity and higher affinity for the HA1 region of A (H1N1)pdm09 HA, compared with younger individuals [37, 38] . ADCC antibodies directed to non-HA influenza virus proteins such as the NA protein and M2 proteins may also participate in cross-reactive immunity [31, 32] . We recognize that there are several limitations to our study that warrant future study. First, we had only a small number of individuals >70 years old; future studies should expand the number of such subjects. Second, individuals aged 1-14 years in our study had high preexisting sH1N1 HI titers. We felt that for the fairest comparison of ADCC responses it was important to ensure that younger individuals who were tested had at least some exposure to influenza virus and were not influenza naive before the 2009 A(H1N1) pandemic. Third, the unpaired nature of our samples meant we were unable to directly assess the effects of A(H1N1)pdm09 infection in each individual. Fourth, the viral elimination assays were only performed using A(H1N1)pdm09-infected respiratory epithelial cells. Future studies could analyze ADCC-mediated clearance of cells infected with a range of influenza virus strains.
In summary, sera from individuals >45 years of age commonly had preexisting ADCC activity to A(H1N1)pdm09 HA before the 2009 pandemic. Both the titer of ADCC antibodies to A(H1N1)pdm09 and the elimination of virus-infected respiratory cells significantly increased following the 2009 A(H1N1) pandemic. The correlation between ADCC responses to sH1N1 and A(H1N1)pdm09 in older individuals implicates sH1N1 infection in generating cross-reactive ADCC antibodies toward the A(H1N1)pdm09. We speculate that the induction of longlived cross-reactive ADCC antibodies through vaccination may provide a level of protection from emerging influenza viruses.
Notes
